top of page
  • X
  • LinkedIn
  • Instagram
Asset 1mail.png

Prof. Hermann Einsele at the Multiple Myeloma Hub

  • May 19
  • 1 min read

In a recent discussion on the Multiple Myeloma Hub, Prof. Hermann Einsele from partner UKW shared insights into the future role of anti-CD38 monoclonal antibodies (mAbs) in treating Multiple Myeloma. These therapies, including daratumumab and isatuximab, are increasingly being used in frontline treatment. Notably, the IMROZ Phase III trial showed that adding isatuximab to the standard VRd regimen significantly improved response rates and progression-free survival.


Beyond newly diagnosed cases, anti-CD38 mAbs are being studied in earlier disease stages, such as smoldering multiple myeloma, and in relapsed settings. Their combination with novel agents—including CELMoDs, bispecific antibodies, and CAR T-cell therapies—offers promising strategies to enhance outcomes and overcome resistance.


This evolving role highlights the potential of anti-CD38 antibodies to further reshape the treatment landscape of multiple myeloma.





Comentários


  • X
  • LinkedIn
  • Instagram

Follow Us

Asset 2BW 2.png
eu_funded_en.jpg

Funded by the European Union. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.

© 2023-2025

bottom of page